Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion.
Alessandro Maselli, who will remain President and Chief Executive Officer of Catalent, said, “The completion of this transaction marks a significant milestone for Catalent. As a private company with Novo Holdings’ partnership and support, we are well-positioned to deliver unparalleled outcomes for our customers and the patients they serve, and ultimately create value for our stakeholders. I would like to thank all of our employees for their commitment to making Catalent the incredible company it is today, and I am excited for all that we will accomplish going forward.”
Kasim Kutay, CEO of Novo Holdings, said, “We are pleased to welcome Alessandro and the talented Catalent team to the Novo Holdings family. Catalent plays a key role in driving product development, launch and supply solutions for pharma, biotechnology, and consumer health companies, and its mission is closely aligned with Novo Holdings’ purpose to invest for the benefit of people and the planet.”
“We look forward to supporting the Catalent team as they build on their positive momentum and position the company for future growth to the benefit of customers and patients globally,” added Jonathan Levy, Senior Partner, Novo Holdings.
Comments powered by CComment